RNA-targeted therapeutics
Crooke ST, Witztum JL, Bennett CF, Baker BF · Cell Metabolism, 2018
Crooke ST, Witztum JL, Bennett CF, Baker BF
A broad review of drugging RNA rather than protein. It brings together antisense oligonucleotides, siRNA and related approaches, explaining the shared logic of recognising a target sequence and the pharmacology, safety and delivery challenges common to all of them. A good single reference for the RNA targeted drug landscape.
Related in the Knowledge Hub
From theory to a synthesis ready oligo
Syngenis One designs, screens and orders custom oligonucleotides in one guided workflow. Talk to our team or start designing today.
One engine, working across the whole business.
Syngenis One (AI Discovery)
Design RNA and DNA candidates from target to synthesis ready oligo in one workflow.
Manufacturing
Australia's only commercial RNA facility. Custom oligonucleotides, ordered through Syngenis One.
Research and Diagnostics
AI led therapeutic programs and an aptamer based diagnostics pipeline.
Clinical
A specialist nucleic acid CRO with in silico trial modelling.
Life Care
Consumer genomics at a mass market price.
Fund
Infrastructure that channels research investment into the pipeline.